We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

Intellectual property

We have built a strong intellectual property portfolio to protect both our technology platforms and our therapeutic and diagnostic products. Patent applications have been filed that cover the SupraAntigen™ and Morphomer™ technology as well as composition of matter and disease-specific and product–specific applications of those technologies. The company’s patents and applications are extensive and are grouped into 55 patent families, 340 granted patents and more than 310 pending patent applications.